MARGARET MCELRATH

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)
    Laurence Peiperl
    University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e13579. 2010
  2. pmc Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans
    Samuel O Pine
    Program in Pathobiology, Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e18526. 2011
  3. pmc In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques
    Annelie Tjernlund
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Retrovirology 7:12. 2010
  4. pmc Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1
    Florian Hladik
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Immunity 26:257-70. 2007
  5. pmc Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection
    M Juliana McElrath
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Infect Dis 202:S323-6. 2010
  6. pmc Induction of immunity to human immunodeficiency virus type-1 by vaccination
    M Juliana McElrath
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3 100, Seattle, WA 98109, USA
    Immunity 33:542-54. 2010

Research Grants

  1. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2006
  2. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2002
  3. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2003
  4. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2004
  5. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2005
  6. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2009
  7. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2007
  8. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2001
  9. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET JULIANA MCELRATH; Fiscal Year: 2010

Collaborators

Detail Information

Publications6

  1. pmc Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)
    Laurence Peiperl
    University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 5:e13579. 2010
    ..As secondary outcomes, we also assessed T-cell and antibody responses...
  2. pmc Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans
    Samuel O Pine
    Program in Pathobiology, Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e18526. 2011
    ..Together, these results suggest that vector-specific humoral responses may reduce vaccine-induced T-cell responses by previously undetected mechanisms...
  3. pmc In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques
    Annelie Tjernlund
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Retrovirology 7:12. 2010
    ..SIV and HIV predominantly replicate in lymphoid tissue, but the study of virus specific CD8+ T cells in intact lymphoid tissue is difficult, as traditional in situ tetramer staining requires fresh tissue...
  4. pmc Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1
    Florian Hladik
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Immunity 26:257-70. 2007
    ..Our findings shed light on the very earliest steps of mucosal HIV infection in vivo and may guide the design of effective strategies to block local transmission and prevent HIV-1 spread...
  5. pmc Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection
    M Juliana McElrath
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Infect Dis 202:S323-6. 2010
    ..Presented here are key findings in these vaccine studies with relevance to the development of future vaccines to control acute HIV-1 infection...
  6. pmc Induction of immunity to human immunodeficiency virus type-1 by vaccination
    M Juliana McElrath
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3 100, Seattle, WA 98109, USA
    Immunity 33:542-54. 2010
    ....

Research Grants10

  1. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2006
    ..abstract_text> ..
  2. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2002
    ..These insights can be applied to vaccine design, to assess induction of immune responses by HIV vaccine candidates and to guide the definition of endpoints related to vaccine efficacy. ..
  3. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2003
    ..These insights can be applied to vaccine design, to assess induction of immune responses by HIV vaccine candidates and to guide the definition of endpoints related to vaccine efficacy. ..
  4. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2004
    ..These insights can be applied to vaccine design, to assess induction of immune responses by HIV vaccine candidates and to guide the definition of endpoints related to vaccine efficacy. ..
  5. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2005
    ..abstract_text> ..
  6. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2009
    ..abstract_text> ..
  7. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2007
    ..abstract_text> ..
  8. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET MCELRATH; Fiscal Year: 2001
    ..These insights can be applied to vaccine design, to assess induction of immune responses by HIV vaccine candidates and to guide the definition of endpoints related to vaccine efficacy. ..
  9. HIV-1 CELLULAR IMMUNITY IN EXPOSED SERONEGATIVES
    MARGARET JULIANA MCELRATH; Fiscal Year: 2010
    ..abstract_text> ..